This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is the Options Market Predicting a Spike in Kura Oncology Stock?
by Zacks Equity Research
Investors need to pay close attention to KURA stock based on the movements in the options market lately.
KURA Stock Rises More Than 15% This Past Week: Here's Why
by Zacks Equity Research
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kura Oncology (KURA) delivered earnings and revenue surprises of -29.41% and 88.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kura Oncology (KURA) delivered earnings and revenue surprises of 65.08% and 76.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
by Zacks Equity Research
Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.
What Makes Kura Oncology (KURA) a New Buy Stock
by Zacks Equity Research
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Kura Oncology (KURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at an 110.5% upside potential for Kura Oncology (KURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Kura Oncology (KURA) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
Wall Street Analysts Think Kura Oncology (KURA) Could Surge 116%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 115.6% in Kura Oncology (KURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Kura Oncology, Inc. (KURA).
Company News For Jun 17, 2019
by Zacks Equity Research
Companies In The News Are: FB,BXG,ARQL,KURA
Zacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEX
by Zacks Equity Research
Zacks.com featured highlights include Build-A-Bear Workshop, Kura Oncology, Norsk Hydro, Schnitzer Steel Industries and SYNNEX
5 Stocks in Limelight on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Can Kura Oncology (KURA) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Kura Oncology (KURA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
3 Reasons Momentum Stock Investors Will Love Kura Oncology (KURA)
by Zacks Equity Research
Kura Oncology (KURA) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Kura Oncology (KURA) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Kura Oncology (KURA) saw its shares rise almost 7% in the last trading session.
Kura Oncology Starts Dosing Patients in Phase II CMML Study
by Zacks Equity Research
Kura Oncology (KURA) dosed the first patient in a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia.